Abstract: An apparatus (e.g., for cell culture for in vitro growth of tissues and/or organs) includes a base, a plate on the base, and a removable barrier component on the plate. The removable barrier component is configured to at least partially define a first region. The removable barrier component includes a bottom surface and a top surface. The bottom surface configured to be in contact with the plate. The top surface is opposite the bottom surface. The press is configured to engage the top surface of the removable barrier component to apply a predetermined pressure to the removable barrier component. The removable barrier component is between the press and the plate. A joint between the plate and the removable barrier component may be substantially impermeable to live cells. The apparatus may further include a removable cover that engages the base to enclose the plate, the removable barrier component, and the press.

Abstract: A method for fabricating an organic electronic device comprises providing a plurality of photoresist structures on a substrate, the substrate having a first electrode layer, the photoresist structures having a bottom surface attached to the substrate and a top surface opposite the bottom surface, the top surface having a dimension greater than a dimension of the bottom surface, positioning a mask over the structures, the mask having a plurality of openings, and depositing an emissive material over the substrate through at least one of the plurality of openings to form at least one emissive element. An organic electronic device and a method of fabricating an organic electronic component are also described.

Abstract: A method of fabricating a light emitting device comprises providing a mold having an unpolished surface with an arithmetic mean roughness Ra in a range from 0.1 ?m to 10 ?m, depositing a thin polymer film over the surface of the mold, wherein the film has a thickness in a range from 1 ?m to 100 ?m, positioning a light emitting body onto the thin polymer film, wherein the light emitting body includes an anode, a cathode, and a light emitting layer positioned between the anode and the cathode, and separating the thin polymer film with the light emitting body from the mold. A light emitting device is also described.

Abstract: Provided herein are methods of treatment, compositions, systems and kits using polymer particles as restraints of neutrophil function. Such methods include, but are not limited to, methods of preventing, treating, and/or ameliorating inflammatory diseases, infections, autoimmune diseases, malignant diseases, and other diseases or conditions in which neutrophils may be implicated. In some embodiments, polymer particles are useful for diagnosing neutrophil related diseases or conditions.

Abstract: A device includes a support structure having a plurality of concentric cuts through the support structure that define a set of structure sections. The device also includes an insert assembly supported by the support structure at an inner structure section of the set of structure sections. The inner structure section is configured to tilt the insert assembly at a tilt angle in accordance with a displacement of a first outer structure section of the set of structure sections.

Abstract: Provided herein is technology relating to immunotherapy and particularly, but not exclusively, to compositions, methods, and kits for immunotherapy and activation of T cells using a peptide-major histocompatibility complex (pMHC) assembled on a protein scaffold for patterned signal presentation of T cell activating ligands to T cells.

Abstract: Apparatus and methods are provided for applying ultrasound pulses into tissue or a medium in which the peak negative pressure (P?) of one or more negative half cycle(s) of the ultrasound pulses exceed(s) an intrinsic threshold of the tissue or medium, to directly form a dense bubble cloud in the tissue or medium without shock-scattering. In one embodiment, a microtripsy method of Histotripsy therapy comprises delivering an ultrasound pulse from an ultrasound therapy transducer into tissue, the ultrasound pulse having at least a portion of a peak negative pressure half-cycle that exceeds an intrinsic threshold in the tissue to produce a bubble cloud of at least one bubble in the tissue, and generating a lesion in the tissue with the bubble cloud. The intrinsic threshold can vary depending on the type of tissue to be treated. In some embodiments, the intrinsic threshold in tissue can range from 15-30 MPa.

Abstract: An OLED device comprises a substrate, a first electrode positioned over the substrate, a second electrode positioned over the first electrode, at least one emissive layer positioned between the first and second electrodes in a first region of the OLED device, and a multilayer dielectric reflector stack, comprising a plurality of dielectric reflector layers positioned between the substrate and the first electrode, wherein the multilayer dielectric reflector stack is configured to form an optical cavity with the emissive layer having a Purcell Factor of at least 3.

Abstract: An optical probe assembly as a confocal endomicroscope includes an optical focusing stage that focuses an output beam onto a sample and a mirror scanning stage that is movable for scanning the output beam in both a lateral two dimensional plane and an axial direction, using a side-view configuration. The side-view configuration allows for output beam illumination and fluorescent imaging of the sample with greater imaging resolution and improved access to hard to reach tissue within a subject.

Abstract: Systems and methods for histotripsy and immunotherapy are provided. In some embodiments, histotripsy can be applied to a target tissue volume to lyse and solubilize the target tissue volume to release tumor antigens. In some embodiments, an immune response of the treatment can be evaluated. In other embodiments, an immune therapy can be applied after applying the histotripsy. In one embodiment, the lysed and solubilized cells can be extracted from the tissue. The extracted cells can be used to create immune therapies, including vaccines.

Abstract: The disclosure generally relates to lipid nanodiscs, in particular to lipid nanodiscs formed from polymers. A lipid nanodisc according to the disclosure includes a lipid bilayer having a first hydrophilic face and a second hydrophilic face opposing the first hydrophilic face, and a hydrophobic edge between the opposing hydrophilic faces, and a polymer encircling the hydrophobic edge of the lipid bilayer. The polymer includes a first monomeric unit having a pendant hydrophobic group and a second monomeric unit having a backbone hydrophilic group. Methods of making and characterizing the lipid nanodiscs are also disclosed.

Abstract: A driving authentication system is presented for a vehicle. The system includes: a dongle interfaced with a battery of the vehicle and an authenticator configured to receive a discharge current from the battery. The dongle operates to modulate discharge current from the battery with an input code; and the authenticator demodulate the input code from the discharge current, compares the input code to the one or more known authentication codes and, in response to the input code matching one of the one or more known authentication codes, controls power capacity of the battery.

Abstract: Synthetic cellular support systems in the form of engineered extracellular matrices are provided. The cellular support system may include a three-dimensional scaffold structure comprising at least one void. At least one suspended fibril spans across the at least one void in the three-dimensional scaffold structure. The suspended fibril comprises at least one extracellular matrix protein, such as fibronectin, and at least one glycan, such as a hyaluronic acid. The suspended fibril is capable of supporting cells and promoting three-dimensional cellular growth. In various aspects, a plurality of suspended fibrils may span the void to form a three-dimensional suspended fibrillar network.

Abstract: A VIVACE converter to harness energy from currents as well as from waves— that is, the present teachings provide a method and apparatus to collect energy from both currents and waves—using the same physical components. The present teachings are particularly useful in that either currents and/or waves may exist on their own nearly everywhere in the oceans and frequently coexist.

Abstract: InGaN/GaN quantum layer nanowire light emitting diodes are fabricated into a single cluster capable of exhibiting a wide spectral output range. The nanowires having InGaN/GaN quantum layers formed of quantum dots are tuned to different output wavelengths using different nanowire diameters, for example, to achieve a full spectral output range covering the entire visible spectrum for display applications. The entire cluster is formed using a monolithically integrated fabrication technique that employs a single-step selective area epitaxy growth.

Abstract: The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

Abstract: A nanowire can include a first semiconductor portion, a second portion including a quantum structure disposed on the first portion, and a second semiconductor portion disposed on the second portion opposite the first portion. The quantum structure can include one or more quantum core structures and a quantum core shell disposed about the one or more quantum core structures. The one or more quantum core structures can include one or more quantum disks, quantum arch-shaped forms, quantum wells, quantum dots within quantum wells or combinations thereof.

Abstract: A natural gas storage material is provided that comprises a porous metal-organic framework (MOF) material having one or more sites for reversibly storing natural gas that contains methane. In certain variations, the MOF has a usable methane storage capacity of greater than or equal to about 208 cm3(STP)/cm3 under pressure swing conditions of 80 bar adsorption to 5 bar desorption at 298 K. In other variations, suitable MOFs having one or more sites for reversibly storing methane with advantageous natural gas storage capabilities are selected from the group consisting of: UMCM-152, DUT-23-Cu, VEBHUG_SL, FUYCIN, ja074366osi20070816_031204, XIYYEL, cg500192d_si_003, VUSKAW, VUSKEA, PEVQOY, EDUSIF, and combinations thereof. Natural gas storage systems and methods of reversibly storing natural gas in such MOFs are also provided.

Abstract: The present disclosure relates to non-destructive methods for collecting data from three-dimensional objects. Method include directing one or more interrogating beams of light towards a surface of a three-dimensional object, where the three-dimensional object includes one or more underlying surfaces, and one or more materials having excitonic properties are disposed on the surface of the three-dimensional object; capturing, using an imaging device, optic response of the one or more materials having excitonic properties to the one or more interrogation beams; and computing, using the imaging device, a distance between the one or more underlying surfaces and the one or more materials having excitonic properties, where the optic response of the one or more materials having excitonic properties is a function of the distance between the one or more materials having excitonic properties and the one or more underlying surfaces.

Abstract: Provided herein is technology relating to predicting a subject's resistance or responsiveness to a decitabine based therapy and particularly, but not exclusively, to methods, compositions, and related uses for predicting a subject's resistance or responsiveness to a decitabine based therapy wherein the subject is diagnosed with chronic myelomonocytic leukemia.